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Table 1
Proposed classification of CFLD.
1. CF related liver disease with cirrhosis/portal hypertension (based on clinical
exam/imaging, histology, laparoscopy)
2. Liver involvement without cirrhosis/portal hypertension consisting of at least
one of the following:
a. Persistent AST, ALT, GGT N2 times upper limit of normal
b. Intermittent elevations of the above laboratory values
c. Steatosis (histologic determination)
d. Fibrosis (histologic determination)
e. Cholangiopathy (based on ultrasound, MRI, CT, ERCP)
f. Ultrasound abnormalities not consistent with cirrhosis
3. Preclinical: No evidence of liver disease on exam, imaging or laboratory values
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Cystic fibrosis (CF) is a common lethal genetic disease in the
North American population, affecting 1:2500 births. There are
about 30,000 individuals in the United States with CF, and
approximately 1,000 new cases annually. Although declining
lung function is the most common cause of mortality in CF
[1–3], liver disease is the third leading cause of death, ac-
counting for 2.5% of overall mortality [4,5]. In this review, we
will outline proposed definitions of liver disease in CF and
review the epidemiology, diagnosis, proposed pathogenesis,
management and outcome of liver disease in CF focusing on
multilobular cirrhosis with or without portal hypertension.
While the liver is likely involved to some degree in all
individuals with CF, most individuals will not develop
cirrhosis, which is what most authors consider clinically
significant liver disease. CF related liver disease (CFLD) is a
nonspecific term without a consistent definition that has been
used to refer to several liver disorders often with wide a spectrum
of severity and impact on outcome, leading to confusion when
comparing disease history, treatment, and outcomes. The
spectrum of liver disease in variably included in CFLD has
included neonatal cholestasis, elevated aminotransferases,
hepatic steatosis, hepatic fibrosis, focal biliary cirrhosis and
multilobular cirrhosis with or without portal hypertension. We
suggest that uniform definitions would lead to consistently
defined clinical and pathologic manifestations and contribute to
clarity in research on the prevalence, natural history and treatment
of liver disease in CF.
The identification of individuals with CF who are at risk for
or who will subsequently develop cirrhosis has been difficult
[6]. As new therapies including those that improve the function
of the cystic fibrosis transmembrane regulator protein (CFTR)
become available, there will be the potential to prevent or
reverse clinically significant liver disease in CF. Thus there will
be a new impetus to identify individuals at risk for advanced
liver disease and those with pre-cirrhotic hepatic fibrosis.
Broad definitions and classifications of CFLD have been
traditionally been used. The 1999 CF guidelines defined liver
disease as the presence of either clinical or biochemical liver
disease [7]. Several recent publications have used the following
definition: The presence of at least 2 of the following conditions
on 2 or more consecutive examinations over a 6–12 month
period [8–10]: 1. hepatomegaly, with liver edge N2 cm below
costal margin in the midclavicular line and confirmed by ultra-
sound. 2. at least 2 of the 3 of AST, ALT and GGTP above the
upper limit of normal and 3. William's score of ultrasound
abnormalities ≥4 [11] Both definitions include many disparate
types of liver disease variable impact on outcome. Recent reports
on the prevalence of CFLD using the broader criteria listed
above, found a 30–40% prevalence of liver involvement in
children and adults with CF [9,10,12]. However, longitudinal
studies found that only 20–30% of individuals with CF de-
velop focal biliary cirrhosis and at most 5–10% will develop
multilobular cirrhosis [4,5,10]. Thus the broad definitions of
CFLD above tend to overestimate the impact of liver disease in
CF.In part due to the variability in definitions, in 2007 the CF
Foundation convened a group of hepatologists who proposed
the classification of liver involvement in CF shown in Table 1.
This classification separates cirrhosis with or without portal
hypertension from other forms of liver disease such as elevated
aminotransferases, hepatic steatosis and imaging abnormalities
and defines the criteria for considering an individual as having
no current clinical evidence for liver involvement in CF,
primarily for the purposes of research.
The definitions, clinical presentations and prevalence data
for each of the categories are described below.2. Cystic fibrosis related cirrhosis with and without portal
hypertension
2.1. Multilobular cirrhosis
Multilobular cirrhosis differs from focal biliary cirrhosis in the
presence of multiple regenerative nodules and diffuse involvement
of the liver (Fig. 1). Clinically, multilobular cirrhosis is detected by
a hard nodular liver that may or may not be enlarged. On imaging,
there is an irregular nodular liver edge and coarse heterogeneous
parenchyma. Prior to the development of portal hypertension, there
are often no other clinical features. Once portal hypertension is
present, splenomegaly, esophageal or gastric varices, or ascites
may be the first suggestion of previously unsuspected cirrhosis.
Liver biopsy can show features consistent with cirrhosis but
may not be sensitive due to the patchy nature of the nodular
involvement and the large regenerative nodules that can be
mistaken for normal hepatic parenchyma. Multilobular cirrhosis in
CF is a pediatric disorder. The median age of discovery is 10 years
with very few new cases identified after 20 years of age, and no
increased prevalence with increased life span. Our review of 12
reports from the last 20 years involving 4446 subjects from
Europe, Canada, Australia and Israel found an average prevalence
of multilobular cirrhosis of 5.6% portal hypertension 4.2% and
varices 2.4% [4,9,10,12–20].2.2. Portal hypertension without cirrhosis
Interestingly, portal hypertension may predate the onset of
cirrhosis with some patients presenting with non-cirrhotic portal
hypertension. This has been theorized to involve presinusoidal
Fig. 1. Explant of a liver from an individual with CF related cirrhosis demonstrating
involvement of the entire liver with multilobular nodules.
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myofibroblasts with contractile potential [19,21,22].
2.3. Complications of cirrhosis with portal hypertension
The primary complications of CFLD are restricted to indi-
viduals with multilobular cirrhosis with portal hypertension, and
include hypersplenism, esophageal or gastric variceal hemor-
rhage, ascites, and rarely synthetic liver failure with coagulopathy.
The inclusion of liver disorders other than cirrhosis in some
studies of the complications in CFLD, explains much of the
variation in the reported frequency of these complications. While
CFLD is listed as the 3rd leading cause of death among CF
patients, some studies report no increase in mortality among
patients with CF cirrhosis [9,17,18]. Two recent studies report a
trend towards younger age of death in those with cirrhosis
[12,23]. In a large 18 year retrospective review of 1108 patients
with CF, 53 developed cirrhosis, 23 with portal hypertension, 14
with varices, 8 with coagulopathy, 6 with overt liver failure
resulting in 3 liver transplants, but only one reported liver related
death [14]. The incidence rate of major complications of cirrhosis
(bleeding, ascites, encephalopathy) among a cohort of 177 CF
patients (17 who developed cirrhosis) followed longitudinally
was 0.4%, with an all cause mortality rate of 1.6% among
cirrhotic patients [9]. This is in contrast to older reports that
showed 11–19% mortality from variceal bleeding or liver failure
in CF cirrhosis [24].
Once portal hypertension develops in CFLD, some studies
report an increased risk of malnutrition, osteoporosis/hepatic
osteodystrophy, and decline in lung function. The decline in lung
function secondary to portal hypertension has been variously
attributed to intrapulmonary vascular shunting, diaphragmatic
splinting due to organomegaly and ascites, and potentially
increased infections [25–28]. However, a recent retrospective
study of 59 CF patients with cirrhosis and portal hypertension
found no decline in lung function associated with portal
hypertension as compared to age and gender matched CF
specific reference values for lung function [29]. Malnutrition
associated with portal hypertension is likely multifactorial with
decreased nutrient absorption, increased resting energy expen-
diture, anorexia and decreased caloric intake. There may be alink between CFLD and increased insulin resistance leading to
a higher incidence of CF related diabetes [30]. A single center
retrospective case–control study showed an odds ratio of 4.8
(95% CI, 2.49, 9.17) for CF related diabetes in those with
cirrhosis and portal hypertension, using a surrogate marker
(thrombocytopenia) for cirrhosis with portal hypertension [31].
A case–control study of CF patients with and without CFLD
found lower weight, height, and mid upper arm circumference
and lower FEV1 scores in CFLD patients [32].2.3.1. Liver synthetic failure
Only about 10% of individuals with CF and cirrhosis and
portal hypertension progress to liver synthetic failure charac-
terized by a high bilirubin and vitamin K resistant coagulopathy
[23]. This is in contrast to other causes of cirrhosis where the
rate of progression is seemingly much higher.3. Liver involvement without cirrhosis or portal hypertension
There are a variety of other forms of liver involvement in CF.
Some of these may occur together in individual patients.3.1. Focal biliary cirrhosis
FBC is primarily a histologic diagnosis. Autopsy data have
demonstrated liver involvement in 25–72% of adults with CF,
with the majority showing focal biliary cirrhosis [33,34]. FBC
has been found on postmortem exam in 11% of infants, 27% at
1 year and 25–70% of adults [33,34]. It is the pathognomonic
histopathologic liver lesion in CF, and is often clinically silent
without abnormalities in AST, ALT or GGT. On ultrasound, FBC
is characterized by thickened (N2 mm), hyperechoic periportal
tissues. On MRI, there is high intensity signal in the periportal
area on T1 weighted imaging [35]. On liver biopsy, FBC is
characterized by focal portal fibrosis and inflammation, chole-
stasis, and bile duct proliferation. It has been suggested that FBC
is part of the progression to multilobular cirrhosis, but given the
much lower frequency of multilobular cirrhosis compared to
FBC, the progression is very rare [4,9,10,13,15–18,20,21].3.2. Elevations in AST, ALT and/or GGT
Forty to 50% of CF patients have intermittent elevations in
AST, ALT or GGT that are not predictive of the development or
presence of significant fibrosis. In a longitudinal study of over
250 children identified by newborn screen in Colorado, followed
for up to 20 years, 90% had at least one abnormal ALT and 30%
had persistently (N6 months) elevated ALT. Persistent elevations
of AST, ALT or GGTmore than 3 times the upper limit of normal
were very rare [36]. Additionally, patients can have cirrhosis with
portal hypertension and have normal AST, ALT and GGT.
Persistently elevated ALT or GGT (for more than 6 months) are
common and warrant further investigation but are not diagnostic
of any particular disorder [37].
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Steatosis is likely the most common hepatic finding in CFwith
a prevalence of 23–75% of CF patients in all age categories [38].
Steatosis was present in 70% of children undergoing liver biopsy
for suspected liver disease [17,21]. Hepatic steatosis has been
associated with malnutrition, and deficiencies of essential fatty
acid, carnitine and choline. However, steatosis is also found in CF
patients with adequate nutritional status [5]. It presents as smooth
mild hepatomegaly without signs of portal hypertension. The
appearance on ultrasound is typically uniform hyperechogenicity,
but it may also have a heterogeneous appearance on ultrasound
or as one or several “pseudomasses,” which are lobulated fatty
structures 1–2 cm in size [39,40]. In one study, 57% of cases of
steatosis detected on ultrasound were associated with elevation in
aminotransferases [41]. A note of caution is warranted in regards
to this finding as the ultrasound findings may not be specific for
steatosis and can be seen in periportal fibrosis [7]. Thus histology
is still the gold standard for the diagnosis of hepatic steatosis.
4. Biliary tract disease
4.1. Cholangiopathy
Magnetic resonance cholangiography (MRC) demonstrates
abnormalities in the intrahepatic bile ducts in a significant
number of CF patients, with structuring, beading, and areas of
narrowing and dilatation similar to primary sclerosing cholangitis
[39]. MRC detected intrahepatic biliary anomalies were reported
in 69% of CF patients regardless of laboratory or clinical
evidence of liver disease, with isolated or multiple dilations in the
biliary tree noted [42].
4.2. Cholestasis
This is the earliest manifestation of liver involvement in CF
and may mimic biliary atresia. Less than 2% of infants with CF
present with neonatal cholestasis. Meconium ileus is a known
risk factor for the development of cholestasis [5,38,40]. While
cholestasis generally resolves within 3 months with no sequelae,
some studies have suggested an increased risk for cirrhosis in
children with meconium ileus [4,9,10].
4.3. Gallbladder involvement
Gallbladder abnormalities are found in 24–50% of CF patients
by US, MRI or MRC. Microgallbladder is reported in 5–45% of
CF patients and 3–20% has gallbladder distention and evidence
of gallbladder dysfunction. Older studies reported that gallstones
develop in 3–25% of pediatric CF patients [38,39,43]. These
stones are more commonly calcium bilirubinate stones [44].
Coinheritance of the Gilbert syndrome associated UGT1A1
mutation appears to increase the risk for gallstones in CF [45].
Cholecystectomy is indicated for the management of symptom-
atic cholelithiasis. Calcium bilirubinate stones do not respond to
ursodeoxycholic acid treatment. No treatment is required for
microgallbladder.5. Pathogenesis
The pathogenesis of CF liver disease is largely unknown. In
the liver, CFTR is localized to the apical surface of bile duct
epithelium and is not found in hepatocytes [46]. CFTR in biliary
epithelium increases apical biliary chloride secretion primarily
increasing bile acid independent bile flow. In the pancreas and
lung, CFTR is similarly located in the apical epithelium. These
organ systems are affected to varying degrees by a dysfunctional or
absent chloride channel leading to thickened mucus secretions and
plugging. A similar pathologic mechanism has been suggested in
the liver, with inspissated bile leading to obstruction of small
intrahepatic bile ducts. This has been hypothesized to lead to
accumulation of toxic bile acids in the liver, depletion of hepatic
antioxidants, and liver cell injury. Repeated liver cell injury can
activate hepatic stellate cells, which can lead to hepatic fibrosis and
in some cases cirrhosis [5–7,47,48]. An alternative theory of
pathogenesis is that increased intestinal permeability in CF leads to
absorption of pathogen associated molecular patterns that stimulate
inflammation and fibrosis [49–53]. It is unknown why only a
subset of CF patients develop cirrhosis, while the majority of
individuals with a similar CFTR defect do not develop cirrhosis.
Cirrhosis occurs predominantly in those individuals with more
severe class 1, 2, and 3 mutations and pancreatic insufficiency, but
no specific genotype/phenotype correlation exists. In a study of
genetic modifiers in CF cirrhosis, the PiZ heterozygote state for
alpha-1 antitrypsin (SERPINA1 Z-allele) was associated with an
increased risk for cirrhosis and a population attributable risk of 7
percent, but accounted for only 9% of the cirrhotics [54]. Other
factors inconsistently associated with cirrhosis have been male
sex, meconium ileus and TGF-B1 polymorphisms [9,10,54–57].
Further investigation of the pathogenesis of CF cirrhosis will
hopefully aid in the development of targeted therapies.
5.1. Screening for liver disease
The goals of screening for liver disease in CF are two-fold.
The first would be to identify individuals at risk for cirrhosis prior
to its development in order to institute therapy to prevent or
reduce progression to cirrhosis. The second would be to detect
patients who have developed clinically silent cirrhosis to allow
monitoring and interventions to reduce or mitigate complications.
There are no tests to reliably identify individuals with CF who
are at high risk for the development of cirrhosis. In contrast,
several methods have shown promise for the detection of
clinically silent cirrhosis. A combination of physical examination
for hepatomegaly, annual testing of AST/ALT and GGT, and
abdominal imaging (ultrasound, CT or MRI/MRC) have been
thought to hold the best promise for detecting clinically relevant
liver disease in CF (cirrhosis with or without portal hypertension
or advanced hepatic fibrosis). However, to date, these tests have
not been shown to be sensitive for early stages of hepatic fibrosis
or the identification of individuals who are at high risk for
cirrhosis. In a prospective cohort study of CF patients with
suspected CFLD, dual pass needle core liver biopsy increased the
sensitivity of the detection of hepatic fibrosis by 22% compared
to a single pass liver biopsy. In this study, the finding of more
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associated with the future development of portal hypertension.
Clinical exam, ultrasound and ALT were not predictive of
development of portal hypertension. Clinical hepatomegaly and
ultrasound abnormalities were found to be sensitive, but not
specific, and ALT elevation specific but not sensitive for the
detection of advanced fibrosis on biopsy [21].
The CF guidelines from 1999 recommend an annual physical
exam for liver span and texture, spleen size and annual AST,
ALT and GGT determination, but contained no definitive
recommendations on screening imaging or liver biopsy. A recent
Best Practice guideline paper from the European Cystic Fibrosis
Society recommends hepatic ultrasound for patients with
persistent elevation of AST, ALT or GGT on 3 consecutive
occasions over 12 months, and/or clinical hepatomegaly or
splenomegaly. They proposed that abnormalities in ultrasound
could be followed by liver biopsy [37].
Liver biopsy remains the “gold standard” for the detection and
staging of hepatic fibrosis and the diagnosis of cirrhosis. The
risks, cost and lack of ability to perform serial measurements with
liver biopsy in large part explain the emphasis on developing
reliable and validated noninvasive tests for liver disease in CF.
Routine liver biochemistries are unreliable as indicators of
cirrhosis or the risk of development of cirrhosis. Several studies
have suggested the use of serum markers of hepatic fibrogenesis
for early detection of CF liver disease, such as TIMP-1, collagen
type IV, prolyl hydroxylase and glutathione s-transferase
[48,58–60]. Composite tests of serum biomarkers for the
prediction of hepatic fibrosis have been utilized in adults with
hepatitis C. Aspartate aminotransferase to platelet ratio index
(APRI) has also been used to predict severe fibrosis and cirrhosis
in chronic liver disease such as hepatitis C, but does not predict
milder forms of hepatic fibrosis. Neither composite tests, nor
APRI have been systematically studied in CFLD.
5.2. Radiologic imaging
The three main imaging modalities: ultrasound, CT and MRI
can detect cirrhosis with or without findings of portal hyperten-
sion [11]. Ultrasound can demonstrate multilobular nodularity
indicative of cirrhosis, but is unreliable at detecting earlier stages
of hepatic fibrosis. Steatosis and hepatic fibrosis may be
indistinguishable. Children with normal hepatic ultrasounds can
have advanced fibrosis [17]. The finding of a normal ultrasound
does not indicate low risk for development of cirrhosis in a
younger child, as children with a normal US have been shown to
progress to cirrhosis, albeit at an unknown rate [16,61]. The
presence of abnormalities in ALT or GGT is not predictive of
ultrasound findings [16], although abnormal ultrasound findings
were associated with abnormalities in ALT or GGT [41].
Ultrasound findings of hyperechogenicity have been intermittent
in longitudinal studies [16], and consistency in interpretation of
echogenicity and homogeneity may be center dependent leading
to increased inter-observer variability [16,41,61]. However some
centers perform serial routine abdominal ultrasound to detect early
imaging abnormalities such as parenchymal heterogeneity that
may indicate an increased risk for progression to cirrhosis [16].MRI, when combined with MRCP, has the advantage of
being able to detect abnormalities in intra and extraheptic bile
ducts as well as significant periportal fibrosis and nodularity in
the liver parenchyma [39]. Newer MRI modalities are also able
to accurately determine the fat content of the liver and may aid
in the detection of hepatic steatosis [62]. The role of diffusion
weighted MRI imaging in the detection of early fibrosis and the
differentiation between mild and severe fibrosis is under study.
Acoustic transient elastography uses a low frequency acoustic
wave transmitted through the liver via a probe placed on the skin
over the liver. The velocity of the wave propagation is directly
proportional to the stiffness of the liver due to its collagen
fiber content. It is a well validated test for the detection and
quantification of advanced hepatic fibrosis and cirrhosis in adults
with hepatocellular disease, primarily hepatitis C, but seems to
only reliably detect advanced fibrosis versus normal and mild
fibrosis, and is not yet able to differentiate mild fibrosis from no
fibrosis [63–67]. Adult studies have shown less intra and inter-
observer variability of transient elastography compared to
ultrasound, and a faster learning curve when utilized by novice
readers [68]. There are limited studies of elastography in CF. Two
studies of children and adults with CF found increased liver
stiffness in clinical and biochemical CFLD and elastography
compared favorably to ultrasound for the detection of advanced
fibrosis [60,69]. Two studies in CF found a good correlation
between transient elastography values and the presence of
esophageal varices [60,70]. It is possible that there will be greater
value in serial measurements of elastography, but, further studies
are needed to evaluate elastography in CF.
Magnetic resonance elastography (MRE) is a new technol-
ogy that holds promise for measurement of liver fibrosis and
detection of earlier stages of hepatic fibrosis [71,72].
Acoustic radiation forced impulse imaging (ARFI) uses
ultrasound to measure liver stiffness and shear wave velocities.
A potential advantage is that ARFI may not being influenced by
hepatic steatosis [68,72]. Initial studies show a good correlation
with transient elastography. One report in a small cohort of CF
subjects suggests that ARFI is similar to transient elastography
[73].6. Treatment and outcome
To date, there is no effective therapy in CF to prevent or treat
fibrosis. Thus, most efforts are directed at supportive care and
management of complications.6.1. Infants
Infants with cholestasis and prolonged jaundice are at risk for
malnutrition, fat-soluble vitamin deficiency, and growth failure.
This risk is higher in those infants who have undergone bowel
resection. Close monitoring of growth and fat-soluble vitamin
status with institution of higher calorie feedings and fat-soluble
vitamin supplementation often required. Ursodeoxycholic acid
(UCDA) increases bile flow and has been used in this setting
despite the lack of published evidence in this age group.
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In older children and adults with CF and cirrhosis, the main
issues in care are screening for and management of complications
of portal hypertension (splenomegaly, ascites, varices) and
optimization of their nutritional status and lung function. In
cirrhosis, it is advisable to avoid hepatotoxic medications and
alcohol, and immunize against hepatitis A and B. In patients with
portal hypertension NSAID's should be avoided due to the
increased risk of GI bleeding.
6.2.1. Ursodeoxycholic acid
UDCA at present is the only therapy available that may possibly
prevent or delay progression of CFLD. It increases bile flow, may
replace potentially toxic bile acids, acts as a cytoprotective agent,
and possibly stimulates bicarbonate secretion in the biliary tract
[6,7,26]. UDCA at 15–20 mg/kg/day has been shown to improve
AST and ALT, bile drainage, liver histology, and nutritional and
essential fatty acid status in CF liver disease. However, a 2000
Cochrane review on the use of UCDA in CF found few suitable
randomized trials assessing UDCA efficacy and there have not
been any randomized studies conducted since that review. They
concluded data are insufficient to justify routine use in CF, and
no data on impact of UCDA on death or liver transplant are
available. A recent study of higher dose UDCA in primary
sclerosing cholangitis was terminated early due to an increased
risk of death or liver transplantation in the UDCA group [74]. In
summary, there is significant disagreement about the use of
UDCA in CF [7,37,75]. There remains no well controlled
randomized study of UDCA in CF and no strong evidence for
benefit or harm in CF. Further study is needed to clarify the
potential role of UDCA in CF. Other potential therapies such as
essential fatty acid supplementation and antioxidants have not
been sufficiently investigated to provide any recommendations.
7. Management of CF cirrhosis with portal hypertension
7.1. Screening
In patients with known cirrhosis, periodic assessment for
sequelae of cirrhosis and portal hypertension is important.
Abdominal examination should be performed at least annually for
splenomegaly and/or ascites that can indicate advancing portal
hypertension. Platelet count should be determined at least
annually. Platelet counts b150,000 units×103/μL can indicate
hypersplenism and has been shown to correlate with an increased
risk of development of esophageal or gastric varices [76]. Periodic
abdominal ultrasound with Doppler velocity measurements
should be performed to screen for hepatocellular carcinoma,
measure spleen size, assess ascites, portal venous velocities and
presence of varices.
7.2. Esophageal and gastric varices
Esophageal and gastric varices occur as a consequence of
portal hypertension. In CF patients with cirrhosis, varices have
been reported to be present in anywhere from 30–100%[4,9,10,13,14,18]. In total these studies reported on 3057 patients
with CF with 111 patients (3.6%) with cirrhosis identified in
whom 54 (48%) had varices. The risk of variceal bleeding in CF
cirrhosis has not been well studied. In 2 studies of a total of 67
patients with CF and cirrhosis, 28 (42%) developed variceal
hemorrhage [12,24]. Several methods of assessing the risk of
bleeding from varices exist. These include the ratio of the spleen
size to platelet count, transient elastography, wedged hepatic
venous pressure and endoscopy. In adults with other causes of
cirrhosis, screening endoscopy is cost effective due to an
increased mortality following esophageal variceal hemorrhage.
In children this has not been demonstrated. Thus the use of
screening endoscopy for varices and primary variceal prophy-
laxis remains controversial in the care of children and adults with
CF with cirrhotic liver disease. It is clear though that once
variceal hemorrhage occurs, variceal eradication is indicated.
However, the high frequency of variceal hemorrhage in patients
with cirrhosis and portal hypertension in CF has led many centers
to consider primary variceal prophylaxis.
Primary variceal prophylaxis is the management of varices
before a hemorrhage has occurred. The two modalities are
pharmacotherapy with non selective β-blockade and endoscop-
ic variceal eradication. CF patients with cirrhosis are often poor
candidates for pharmacotherapy due to the pulmonary side
effects of β-blockade. In addition, β-blockers have not shown
to be effective in preventing variceal bleeding in children [77].
There is no evidence in children that supports primary variceal
prophylaxis. There is evidence in adults with cirrhosis and
portal hypertension from other causes that supports primary
variceal prophylaxis [78]. If a decision is made to pursue
primary variceal prophylaxis, endoscopic variceal band ligation
is the treatment of choice [77,78].
Secondary variceal prophylaxis is treatment to prevent re-
bleeding after a variceal hemorrhage has occurred. In this setting
variceal band ligation is the preferred approach. If variceal band
ligation is unsuccessful or if gastric varices are present, options
include cyanoacrylate glue for control of gastroesophageal
variceal bleeding and β blockade [79]. Refractory cases may
require radiologic or surgical measures as secondary prophylaxis.
These methods include a transjugular intrahepatic portosystemic
shunt (TIPS), selective (splenorenal) or non selective (mesocaval,
portocaval) portosystemic shunt. Some authors have used partial
splenic embolization or partial or total splenectomy in an attempt
to reduce portal venous flow and improve thrombocytopenia.
Indeed, partial splenectomy with splenorenal shunt had favorable
outcome in 15 of 19 CF patients with portal hypertension, with
improvement in liver function and portal hypertensive symptoms,
significantly delaying or obviating the need for liver transplan-
tation [80].
7.3. Hypersplenism
Hypersplenism can complicate portal hypertension resulting
in sequestration of up to 90% of platelets within the spleen.
Persistent severe thrombocytopenia may be an indication for
partial splenic embolization [81–83] or total splenectomy in
some cases [80,84,85]. Risks of total splenectomy and the
122 T. Flass, M.R. Narkewicz / Journal of Cystic Fibrosis 12 (2013) 116–124immune ramifications must be weighed with the potential
benefits of this procedure, with many centers not recommending
this procedure [86,87].
7.4. Ascites
The development of ascites represents a poor prognostic
sign, and is indicative of relative hepatic decompensation and
the need for evaluation for possible liver transplant. Diuretics
such as furosemide or spironolactone may be utilized as first
line therapy in concert with a salt and fluid restricted diet in
attempts to decrease the ascitic fluid load. Spironolactone is
often preferred as first line therapy because of the potassium
sparing effects, but monitoring for hyperkalemia is warranted.
Care must be taken to not overly restrict salt in CF, as
hypochloridia may result especially in the summer months.
Spontaneous bacterial peritonitis can complicate ascites and
should be considered in the setting of fever or abdominal pain
without a source in a patient with ascites. Significant ascites
can lead to respiratory compromise and renal decompensation,
and may warrant large volume paracentesis [88].
7.5. Encephalopathy
Hepatic encephalopathy is rare in CF patients with cirrhosis.
In most of the reports of encephalopathy, it developed after
portosystemic shunting for portal hypertension. Management
includes lactulose, oral non-absorbable antibiotics and provision
of adequate calories to avoid catabolism.
7.6. Liver transplantation
Which patients with CF and cirrhosis require liver transplant,
and optimal timing of transplantation remains a controversial
subject. Reserving liver transplant only for those with liver
synthetic failure (a relatively rare late event in CF cirrhosis)
versus early transplantation following the development of portal
hypertensive complications varies by center. The established
indications for liver transplant in CF would include cirrhosis with
evidence for hepatic decompensation or uncontrollable variceal
bleeding. Some authors feel that evaluation and transplantation
should occur earlier in the disease course, before lung function is
severely compromised when outcomes are likely to be better
[25,89]. The relatively preserved hepatic synthetic function in the
CF cirrhosis population affects prioritization for liver transplant,
and clear guidelines on selection of CF patients for liver
transplantation are lacking, although a scoring system has been
proposed [90].
Of 203 liver transplants in CF patients performed in the US
from 1987–2008, 148 were performed in children. There was a
significant survival advantage in both adults and childrenwith CF
cirrhosis receiving liver transplant compared to those with
cirrhosis who did not receive a transplant, with further survival
advantage in children compared to adults [91,92]. Outcomes of
liver transplant in CF have generally been favorable with 1 year
patient and graft survival (89%/83% respectively), and 5 year
patient survival rates (85.8%) not significantly different thannon-CF liver transplant patients [87,92]. However, for CF
patients without liver synthetic failure or intractable GI bleeding,
their one year survival without transplant would likely be higher.
In Europe, the median age of CF liver transplant recipients was
12 years and the 3 year survival was approximately 80% [93].
Thus pediatric CF patients in the US and Europe who undergo
liver transplant experience survival rates similar to the 5 year
unadjusted survival rates of 86% in US non-CF pediatric liver
transplant recipients [92].
Relative contraindications to an isolated liver transplant in CF
include infection with multi-drug resistant organisms (Pseudo-
monas, Burkolderia), poor pre-transplant pulmonary function
(FEV1 b50% predicted) and/or elevated resting arterial pCO2,
extensive pulmonary fibrosis on imaging, and severe pulmonary
hypertension [86,93]. Short term improvements in lung function
are reported in pediatric patients following liver transplant, and
poorer lung function prior to surgery has been positively
associated with mortality risk [86]. Small single center series
have reported both favorable [25] and unfavorable pulmonary
function outcomes following liver transplantation [94]. A recent
analysis of the CF registry shows no difference in the rate of
decline in FEV1 in the 3 years following liver transplant in the
CF subjects who underwent liver transplant compared to CF
controls without liver disease [95]. This suggests that liver
transplantation does not lead to a significant long term change in
pulmonary outcome. The effect of liver transplant on the
nutritional status of CF patients is also uncertain, with reports
of improvements [96,97] and reports of no improvement [95].
Combined lung and liver transplant may be considered in
patients with cirrhosis and portal hypertension and extensive
pulmonary fibrosis, lower FEV1 and higher resting pCO2.
Eleven CF patients underwent combined liver–lung transplanta-
tion between 1987 and 2004 in the US. The median age was
15 years, and 1, 3 and 5 year patient survival rates were 79%,
63% and 63% respectively [98]. Eleven combined liver–pancreas
transplants in CF patients with cirrhosis and CFRD were per-
formed between 1987 and 2010, with 100% five-year survival
reported in follow up of 7 patients, with no further requirement
for exogenous insulin or pancreatic enzyme replacement therapy
[87].
8. Summary
Although some degree of liver involvement in CF is common,
cirrhosis and subsequent portal hypertension is a rare but serious
complication seen in only 5–10% of CF patients. Efforts are
underway to better define and understand the nature of this
condition and to identify which patients are at risk for the
development of cirrhosis. Early detection has proven to be
elusive, with many patients identified after cirrhosis and portal
hypertension have already developed. Cirrhosis impacts the
nutritional and pulmonary status of affected patients, but pul-
monary status remains the primary determinant of outcome. In
the rare patient with hepatic decompensation or significant
complications that cannot be managed medically, liver trans-
plantation may be an option. Future efforts should focus on
developing accurate methods of detecting individuals at risk for
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trials of potential interventions to mitigate or prevent/reverse
fibrosis prior to development of cirrhosis and portal hypertension.References
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